Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 148.93M | 133.01M | 127.79M | 111.59M | 99.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.93M | 133.01M | 127.79M | 111.59M | 99.41M |
| Cost of Revenue | 28.26M | 25.54M | 23.42M | 23.02M | 22.78M |
| Gross Profit | 120.67M | 107.47M | 104.36M | 88.57M | 76.63M |
| SG&A Expenses | 74.13M | 61.91M | 63.29M | 57.71M | 56.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.50M | 130.41M | 132.77M | 126.77M | 123.64M |
| Operating Income | -4.57M | 2.60M | -4.99M | -15.18M | -24.22M |
| Income Before Tax | -4.96M | 2.64M | -5.46M | -13.65M | -24.37M |
| Income Tax Expenses | 767.00K | -262.00K | 402.00K | 1.03M | -576.00K |
| Earnings from Continuing Operations | -5.73M | 2.91M | -5.86M | -14.68M | -23.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.73M | 2.91M | -5.86M | -14.68M | -23.79M |
| EBIT | -4.57M | 2.60M | -4.99M | -15.18M | -24.22M |
| EBITDA | 1.51M | 8.67M | 1.07M | -9.13M | -18.17M |
| EPS Basic | -0.11 | 0.06 | -0.12 | -0.30 | -0.50 |
| Normalized Basic EPS | -0.06 | 0.03 | -0.07 | -0.17 | -0.32 |
| EPS Diluted | -0.12 | 0.05 | -0.12 | -0.30 | -0.50 |
| Normalized Diluted EPS | -0.06 | 0.03 | -0.07 | -0.17 | -0.32 |
| Average Basic Shares Outstanding | 50.20M | 50.64M | 49.73M | 48.89M | 47.52M |
| Average Diluted Shares Outstanding | 50.20M | 56.99M | 49.73M | 48.89M | 47.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |